CytoSorbents receives $3.8 million DARPA contract
The program is meant to treat sepsis, an extreme immune response to serious infection that can lead to severe inflammation, organ failure and death. DARPA is funding the project so that CytoSorbents can develop a blood purification system that can remove cytokines, toxins, pathogens, activated cells and biowarfare agents from the blood.
"The threat of a biowarfare attack with toxins such as ricin and botulinum remains a perennial concern," Phillip Chan, CytoSorbents' CEO, said. "Our porous polymers are ideally suited to achieve the broad spectrum removal that is needed to counter most of these agents."
Under the terms of the contract, the company will develop broad spectrum, next generation, porous polymers that are able to remove biowarfare agents and toxins from whole blood. The contract sets aside $1.5 million in funding in the first of five years based on achieving certain milestones.
"Because of the maturity of our technology, we are confident in our ability to meet DARPA's timetable for technology development and strict performance metrics," Chan said. "Over the past several months, we have also collaborated with some of the leading potential systems integrators, to include our technologies into their integration proposals, under a separately funded DARPA DLT solicitation."